Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK announces EMA accepted for review MAA for depemokimab
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP).
GSK announces EMA accepted for review the MAA for depemokimab
GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use
EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP
EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced
Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted indications are for add-on maintenance treatment of asthma in adult and adolescent patients
GSK announces new drug applications accepted for review in China, Japan
GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and
GSK Depemokimab accepted for review by EMA for use in asthma with type 2 inflammation, CRSwNP
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications.The
GSK's depemokimab under review in China and Japan for asthma, CRSwNP
According to InvestingPro analysis,
GSK
maintains a "GREAT" financial health score, positioning it well for continued pharmaceutical innovation. If approved,
depemokimab
would be the first ultra ...
pharmaphorum
2d
Stopwatch starts on reviews of GSK's long-acting asthma drug
Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...
Pharmabiz
1d
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...
2d
GSK says asthma and nasal polyps therapy under EU review
GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Black boxes recovered
Los Angeles wildfire updates
Cause of death revealed
Asteroid may hit Earth
Signs education orders
Ex-worker admits to theft
Michigan priest loses license
Blames DEI for crash
Olympic gold medalist dies
Hamas confirms death
Accused of sexual misconduct
2 more victims in indictment
DOJ weighs dropping case?
'As Tears Go By' singer dies
Searching for joyriders
S3 release date revealed
Senate confirmation hearing
Ebola outbreak in Uganda
Shiffrin finishes 10th
Nashville bids for franchise
Wildfire erupts in NC
Deputy shooting sentence
Syria’s transitional pres
Day 2 of Senate hearing
Weekly jobless claims fall
DOJ sues to block deal
Ground stop amid IT outage
Hamas frees more hostages
First spacewalk together
FDA approves painkiller
US economy grew 2.3%
Feedback